Trump Administration Takes Stake in USA Rare Earth to Boost U.S. Critical Minerals Supply 
ANTA Sports to Acquire Major Stake in Puma in €1.5 Billion Deal, Signaling Strategic Revival 
Embraer Targets Growth as Regional Jet Demand Surges Post-Pandemic 
Citigroup Faces Lawsuit Over Alleged Sexual Harassment by Top Wealth Executive 
Delta Air Lines Operates Reduced Flight Schedule as Winter Storm Disrupts U.S. Travel 
Hermès Menswear Marks Historic Transition as Véronique Nichanian Bids Farewell in Paris 
BYD and Exxon Mobil Strengthen Hybrid Technology Partnership 
Noble Corporation Secures $1.3 Billion in New Contracts, Strengthening Offshore Drilling Backlog 
Microsoft Wins Approval to Build 15 New Data Centers in Wisconsin 
Winter Storm Triggers Widespread Flight Cancellations Across U.S. as Airlines Urge Travelers to Rebook 
Shell Plc Downgraded by RBC as Market Headwinds Pressure Valuation 
Ford and GM Near Financing Deal to Support First Brands Group During Bankruptcy 
Trump Lawsuit Against JPMorgan Signals Rising Tensions Between Wall Street and the White House 
Samsung Set to Begin HBM4 Production for Nvidia and AMD 
Ryanair Profit Slumps in Q3 After Italy Antitrust Fine Despite Revenue Growth 
LVMH Investors Watch Earnings Closely as Luxury Recovery Faces New Challenges 
 Annual Meeting - EconoTimes)
SEOUL, South Korea, May 15, 2017 -- ToolGen, Inc. (KONEX, 199800), a biotechnology company specializing in genome editing, presented results from a study highlighting the use of CRISPR/Cas9 nucleases for specific and efficient genome editing in human primary T-cells, without causing severe cell damage and growth retardation in a poster presentation at the American Society for Gene and Cell Therapy (ASGCT) Annual Meeting being held in Washington, DC from May 10-13, 2017.
The poster presentation entitled “Genome editing of human T cells to generate CAR-T cells with enhanced antitumor function” aimed to study the proposed idea that T-cell anergy serves to induce dysfunction in a wide variety of tumor microenvironments. Using CRISPR/Cas9-mediated gene editing, the researchers were able to successfully knock out DGKα, a tolerance-associated gene at an 80% efficiency rate, which allowed T-cells to reverse hypofunction induced by anergy. Based on this result, the researchers combined the lentiviral delivery of CAR and the electroporation of RNP to generate a CRISPR gene-edited CAR-T cell. These edited CAR-T cells demonstrated lower sensitivity to immunosuppressive conditions and were hyper-responsive against tumor cells.
“We are honored to be recognized by ASGCT for our work using CRISPR/Cas9-mediated gene editing,” commented Seokjoong Kim, Research Director at Toolgen. “The data presented in the poster presentation demonstrates preliminary success in utilizing CRISPR/Cas9 nucleases for specific and efficient gene editing in human primary T-cells. The findings suggest that CAR and TCR T cells with a disrupted anergy-related gene may be potent effector cells against various cancers. We believe that these results continue to validate our approach to gene editing and provide support for further research to move our pipeline of opportunities into the clinic.”
The authors of the presentation were Yoon-Young Kim, In Young Jung, Ho Sung Yu1, Seokjoong Kim, R&D Center, Toolgen, Inc., Seoul, South Korea
About ToolGen, Inc.
ToolGen, Inc. is a biotechnology company focused on the development and application of genome editing technologies. It creates, and holds intellectual property rights for essential tools and technologies for editing the genetic information in microbial, plant, animal, and human cells. ToolGen’s mission is to translate the potential of our innovative platform technology into transformative products for biomedicine and agriculture. For more information, please visit www.toolgen.com.
Investor Relations Contact The Ruth Group Tram Bui / Alexander Lobo Phone: 646-536-7035 / 7037 [email protected] [email protected]
